Woolf E J, Matuszewski B
Merck Research Laboratories, Department of Drug Metabolism, West Point, PA 19486, USA.
J Chromatogr A. 1996 Apr 5;729(1-2):211-7. doi: 10.1016/0021-9673(95)01011-4.
A method for the determination of L-702,007, a human immunodeficiency virus type 1 reverse transcriptase inhibitor, and its 6-hydroxy metabolite in human plasma is described. Plasma samples are extracted using phenyl solid-phase extraction columns. The extract is analyzed by HPLC using a column-switching system to remove interferences from late-eluting endogenous components. Fluorescence detection at an excitation wavelength of 314 nm and an emission wavelength of 390 nm is utilized. The assay was validated in the concentration range of 10-200 ng/ml when 1-ml aliquots of plasma were extracted. The assay has been used to support human pharmacokinetic studies.